immune repertoire sequencing
Adaptive Biotechnologies Wins Expanded Medicare Coverage of ClonoSeq in Mantle Cell Lymphoma
The expanded coverage adds to the existing Medicare payment structure for ClonoSeq, which provides coverage for a bundle of tests to assess patient therapy response.
Adaptive Bio 'Confident' of MRD Reaching Profitability in 2025 as Q4 Revenues Rise 4 Percent
Premium
The Seattle-based firm booked $47.5 million in revenues during the fourth quarter while full-year revenues grew 5 percent to $179.0 million.
Adaptive Biotechnologies Gets IVDR Class C Certification for ClonoSeq Assay
The certification makes the ClonoSeq assay available to EU patients and enables Adaptive to process EU clinical trial samples in its US laboratory.
Adaptive Biotechnologies Q2 Revenues Drop 12 Percent as MRD Revenues Soar
The Seattle-based company saw 36 percent growth in its minimal residual disease business while making significant progress in curbing operating expenses.
Breast Cancer Study Highlights Germline Genetic Influence on Tumor Subtype, Aggressiveness
Investigators saw relationships between germline epitope burdens in frequently amplified driver genes and immunoediting-related breast cancer features.